This clinical trial is focused on patients who are receiving a treatment called extracorporeal membrane oxygenation (ECMO). ECMO is a life-support technique used for patients with severe heart and lung problems. The study is investigating two different types of blood thinners, also known as anticoagulants, to see if they can reduce the risk of major bleeding without increasing the risk of blood clots. The two medications being studied are Heparin and Nadroparin Calcium. Heparin is given through a vein, while Nadroparin Calcium is given as an injection under the skin.
The purpose of the study is to find out if using lower doses of these blood thinners can help reduce complications for patients on ECMO. The study will compare the effects of these medications on bleeding, blood clots, and overall survival. Patients will be monitored for up to six months to see how they respond to the treatment. The study aims to improve the safety and effectiveness of ECMO therapy by finding the best way to use these blood thinners.
Participants in the study will receive either Heparin or Nadroparin Calcium, and some may receive a placebo. The study will track various outcomes, including the need for blood transfusions, quality of life, and any complications related to blood clots. By the end of the study, researchers hope to have a clearer understanding of how to best manage anticoagulation in patients undergoing ECMO treatment.



The Netherlands